Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

被引：0
|
作者：
Hui Yu
Ping Chen
Xiuyu Cai
Chen Chen
Xuanye Zhang
Lina He
Yixin Zhou
Shaodong Hong
Bei Zhang
机构：
[1] State Key Laboratory of Oncology in South China,Department of VIP Region
[2] Collaborative Innovation Center for Cancer Medicine,Department of Radiotherapy
[3] Sun Yat-Sen University Cancer Center,Department of Medical Oncology
[4] Sun Yat-Sen University Cancer Center,undefined
[5] Sun Yat-Sen University Cancer Center,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
PD-L1 inhibitors; PD-1 inhibitors; Small-cell lung cancer; First-line therapy; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：637 / 644
页数：7
相关论文
共 50 条
  • [31] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Shang, X. Q.
    Wang, T.
    Chen, G.
    Ma, C.
    Wang, H.
    Jia, X.
    Mei, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
  • [32] Comparison in Therapeutic of Operation Combined with Chemotherapy and with pd-1 and pd-l1 Inhibitors for Stage 2 Small Cell Lung Cancer
    Zhang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1026 - S1026
  • [33] Real-world outcomes in extensive-stage small cell lung cancer with PD-L1 inhibitors in China
    Meng, X.
    Peng, J.
    Li, S.
    Feng, H.
    Meng, R.
    Zhang, L.
    Liu, X.
    Yu, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1420 - S1421
  • [34] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [35] Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer
    Mo, Dun-Chang
    Liang, Zi-Yu
    Chen, Long
    Huang, Jian-Feng
    Luo, Peng-Hui
    Wang, Han-Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (06)
  • [36] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [37] Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    La-Beck, Ninh M.
    Nguyen, Dung T.
    Le, Alex D.
    Alzghari, Saeed K.
    Trinh, Saralinh T.
    PHARMACOTHERAPY, 2020, 40 (03): : 239 - 255
  • [38] The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis
    Yang, Y.
    Xie, Z.
    Pang, P.
    Wang, N.
    Liang, H.
    Zhao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1049
  • [39] Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies
    Luo, Hao
    Song, Guangbin
    Wang, Dong
    Li, Mengxia
    Dai, Nan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
    Peng, Jianfeng
    Zhang, Lemeng
    Wang, Liping
    Feng, Hui
    Yao, Dongmei
    Meng, Rui
    Liu, Xiaomei
    Li, Xiaohua
    Liu, Ningbo
    Tan, Bingxu
    Huang, Zhaoqin
    Li, Shanshan
    Meng, Xiangjiao
    RADIATION ONCOLOGY, 2023, 18 (01)
12345